• BioLineRx posted a net loss of USD 4.3 million in Q2 2026, widening from USD 3.9 million a year earlier.
• Revenue held at USD 0.3 million, little changed from the prior-year quarter.
• R&D expense rose 26.5% to USD 2.9 million, driven mainly by GLIX1 costs and partly offset by lower motixafortide spending.
• G&A expense more than quadrupled to USD 0.9 million, reflecting a prior-year USD 0.8 million reversal of a doubtful-accounts provision.
• Cash and equivalents totaled USD 13.1 million at June 30; management reiterated runway guidance into the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310700PR_NEWS_USPR_____LN36585) on August 31, 2026, and is solely responsible for the information contained therein.